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Abstract
Background: Four studies from sub-Saharan Africa have found a substantial population-level effect of ART provision on
adult mortality. It is important to see if the impact changes with time since the start of treatment scale-up, and as treatment
moves to smaller clinics.
Methods and Findings: During 2002-4 a demographic surveillance site (DSS) was established in Karonga district, northern
Malawi. Information on births and deaths is collected monthly, with verbal autopsies conducted for all deaths; migrations
are updated annually. We analysed mortality trends by comparing three time periods: pre-ART roll-out in the district (August
2002–June 2005), ART period 1 (July 2005–September 2006) when ART was available only in a town 70 km away, and ART
period 2 (October 2006–September 2008), when ART was available at a clinic within the DSS area. HIV prevalence and ART
uptake were estimated from a sero-survey conducted in 2007/2008. The all-cause mortality rate among 15–59 year olds was
10.2 per 1000 person-years in the pre-ART period (288 deaths/28285 person-years). It fell by 16% in ART period 1 and by
32% in ART period 2 (95% CI 18%–43%), compared with the pre-ART period. The AIDS mortality rate fell from 6.4 to 4.6 to
2.7 per 1000 person-years in the pre-ART period, period 1 and period 2 respectively (rate ratio for period 2 = 0.43, 95% CI
0.33–0.56). There was little change in non-AIDS mortality. Treatment coverage among individuals eligible to start ART was
around 70% in 2008.
Conclusions: ART can have a dramatic effect on mortality in a resource-constrained setting in Africa, at least in the early
years of treatment provision. Our findings support the decentralised delivery of ART from peripheral health centres with
unsophisticated facilities. Continued funding to maintain and further scale-up treatment provision will bring large benefits
in terms of saving lives.
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Introduction
HIV/AIDS is responsible for around one half to two-thirds of
deaths among 15–59 year olds in Southern and East Africa, and
both HIV prevalence and incidence remain high[1].
Antiretroviral therapy (ART) can have a dramatic effect in
reducing deaths due to HIV/AIDS, and the Millennium
Development Goals (MDGs) include the target of universal access
to treatment for all those who need it by 2010. Billions of dollars
are being invested in ART programmes to make treatment widely
available[2,3]. Following rapid scale-up of treatment in the last five
years[4], systematic reviews of data from cohorts in non-research
settings in sub-Saharan Africa show that median retention in care
is around 80% (range 55–93%) 12 months after first starting ART,
and around 70% (range 64–87%) 3 years after first starting
ART[5,6], while findings published since mid-2009 are consistent
with this[7,8,9]. Published data on survival and retention in care
from national-level ART treatment programmes in Southern and
East Africa are available from Malawi, Rwanda, South Africa,
Botswana, and Zambia[9,10,11,12,13]. Among all of the 72666
patients who first registered for ART in the public sector in
Malawi during 2004-6, 76% were retained in care 12 months after
starting ART[10]. In Rwanda, retention in care was 86% at 12
months after starting ART, among patients enrolled in the
national ART programme during 2004-5[11], while among the
earliest patients enrolled in Botswana’s government ART
programme around two-thirds were retained in care at 3
years[12].
The proportion of adult mortality that can be averted by ART
provision depends on HIV prevalence, the proportion of HIV-
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infected individuals who know their status and whose eligibility
for ART is assessed, and on the proportion of eligible individuals
who start and stay in treatment programmes. In particular,
mortality and loss to follow-up between the time of first being
identified as eligible for ART and starting treatment can be
high[14,15,16,17,18,19,20].
To date, there are 4 published studies of the population-level
effect of ART roll-out on adult mortality in sub-Saharan
Africa[21,22,23,24]. In Addis Ababa in Ethiopia, cause-specific
mortality data collected from burial sites showed that mortality
due to AIDS fell by around 50% among 20–64 year olds during
the two years after ART was first provided for free[21]. In
KwaZulu Natal district, South Africa, mortality due to AIDS
among 25–49 year olds fell progressively during the ART roll-out
years 2004-6, compared to 2002-3, with a reduction in AIDS
mortality of 22% in women and 29% in men, with no reduction in
non-AIDS mortality[22]. In Thyolo district in southern Malawi, a
setting in which the universal access target of 80% of those
estimated to be urgently in need of ART was reached in 2007,
data on all deaths (child and adult) registered by traditional
authorities indicate that mortality fell by 37% between 2000 and
2007[24]. In Karonga district, northern Malawi, we have
previously shown early evidence of the population-level impact
of ART provision on adult mortality from a demographic
surveillance site (DSS): all-cause mortality in 15–59 year olds fell
by around 10% during the eight months immediately following the
opening of the first ART clinic in the district at the end of June
2005[23].
In Malawi, adult HIV prevalence is around 14%, meaning that
around 1 million adults are HIV-infected. Implementation of the
public sector ART programme began in 2004, and by the end of
2008 around 147000 people were on treatment[25], out of an
estimated 200000 eligible individuals, in around 100 health
facilities[10]. Since our initial study, ART has become available
at additional health facilities in Karonga district, including one
within the DSS area, and the number of individuals accessing
ART has increased substantially. It is important to see whether the
impact of ART changes with time since the start of treatment
scale-up, and whether it can be sustained through small rural
clinics.
In this paper, we present data from the Karonga DSS on
changes in all-cause and AIDS mortality, comparing the first 3
years of ART roll-out in the district, from the beginning of July
2005 to the end of September 2008, with the pre-ART time period
from mid-2002 to mid-2005. We then relate the changes to
estimates of treatment need and ART uptake, and to 12-month
survival and retention in care at the health facility that provides
ART within the DSS area.
Methods
Ethics statement
Ethical approval for the study was granted by the National
Health Sciences Research Committee of Malawi (NHSRC
protocol number 419) and the Ethics Committee of the London
School of Hygiene & Tropical Medicine (ethics committee number
5081). For monitoring of births, deaths, and in- and out-migrations
in the DSS, interviews were only conducted if verbal consent was
given by the household head and by the respective household
members, and consent was documented by the interview sheet that
was filled: the ethics committees both agreed that written consent
was not required. For the HIV sero-survey, written consent was
obtained from all participants.
Karonga district is a rural area in northern Malawi, and most of
the population are subsistence farmers. HIV prevalence in adults
was 2% in the late 1980s, 13% in the late 1990s[26] and 10–14%
during 2000–2008[27]. The first-line ART regimen is a fixed-dose
combination tablet of stavudine, lamivudine, and nevirapine,
taken twice daily[28]. During 2005–2008, individuals were eligible
for ART if they were in WHO clinical stage 3 or 4, or had a CD4
count,250 cells/mm3.
During the period 2002-4 a demographic surveillance site (DSS)
was established in the south of the district in a population of
32000, following a baseline census[29]. Sufficient identifying
information is collected so that all individuals can be traced over
time. Information on births and deaths is collected monthly and
information on individual in-and out-migration is updated once a
year.
Verbal autopsies are conducted for all deaths, allowing AIDS
and non-AIDS deaths to be distinguished[23]. The verbal
autopsies are conducted by health assistants with additional
training, using a semi-structured questionnaire similar to the
INDEPTH tool[30] adapted from the standard World Health
Organization questionnaire. Whenever possible, the informant is a
close relative of the deceased who nursed them through their final
illness, and the information is collected around 4–6 weeks after the
death. Each verbal autopsy questionnaire is independently
reviewed by 2 clinicians, and in the event of discrepancies a third
reviewer makes the decision on cause of death. If a decision cannot
be made on the cause of death, then it is coded as un-specifiable.
Data were double-entered using AccessH and analysed using
Stata 10 (Stata corp., College Station, Texas, USA). Data were
available for analysis from August 2002 up to the end of
September 2008, with person-time calculated from the time an
individual was first resident in the DSS until the earliest of date of
death, out-migration, or end of the follow-up period. If an
individual left and later returned to live in the DSS area, the time
they were away was not counted towards their person-time. For
analysis of AIDS mortality, deaths due to non-AIDS and un-
specifiable causes were censored. For analysis of non-AIDS
mortality, deaths due to AIDS were censored.
Individuals aged 60+ years old were excluded from the analysis
of cause-specific mortality, for two reasons. First, in the pre-ART
period only around 7% of deaths in this age group were attributed
to AIDS: thus, ART could have little population-level effect on
mortality in this group. Second, in this age group 18% of deaths
were of un-specifiable cause. Nonetheless, we present trends in all-
cause mortality among individuals aged 60+ years old, for
comparison with trends in younger individuals.
We defined 3 time periods:
1. The pre-ART period (August 2002- end June 2005);
2. ART period 1 (July 2005–end September 2006), when ART
was available only in a town 70 km from the DSS area;
3. ART period 2 (October 2006–end September 2008), when
ART was available from a clinic within the DSS area.
We also examined mortality separately in the first and second
year of period two, to see if there were any trends within that
period.
Malawi’s north-south highway bisects the study area, with one
spur road to the clinic within the area. Proximity to the tarmac
road facilitates access to the ART clinics, and HIV prevalence is
higher close to this road compared with more remote areas
(unpublished data). Approximately half the population lives within
1 km of the road (hereafter ‘‘rural roadside’’), and the rest more
remotely (hereafter ‘‘rural remote’’). Analyses were stratified by
ART and Mortality in Malawi
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area of residence, age group (15–29 years, 30–44 years, 45–59
years), and sex. Poisson regression was used to calculate rate ratios
(RRs) for the effect of time period, both stratified on and adjusted
for age group, sex, and area of residence. In the stratified analyses,
statistical evidence for whether the effect of time period varied by
each of age, sex, and area of residence was obtained from a test for
interaction.
Between September 2007 and October 2008 an HIV sero-
survey was conducted in the DSS area, offering HIV testing to all
individuals aged 15 or more years old at their own homes, using
rapid tests following a parallel testing algorithm. The sero-survey
included questions on whether an individual had ever taken, or
was currently taking, ART. Cross-sectional analyses of these data
were done to estimate age-, sex-, and area-specific uptake of ART
overall, and also restricted to individuals who tested HIV-positive
during the sero-survey.
Estimation of ART need was based on a Weibull regression
model fitted to age-specific survival patterns of 196 HIV-positive
individuals from a retrospective cohort study conducted 1998–
2000[31], in the same way as previously described in a
comparative analysis of African community study data[32]. The
parameters from the fitted Weibull model were then applied to the
individuals who tested HIV-positive during the 2007/8 sero-
survey, to calculate their predicted probability of death by 3 years
later, on the assumption that an individual who is within 3 years of
death is in need of ART[33]. These predicted probabilities were
then summed to estimate the proportion of HIV-positive
individuals who were in need of ART in 2007/2008, among
those who agreed to give blood for HIV-testing in the sero-survey.
From the end of January 2008, all newly registered HIV-
positive patients at the ART clinic who live within the DSS area
have been invited to join a cohort study. Participants are all able to
access CD4 count testing. Survival analysis of these data was done
to estimate 12-month retention in care after starting ART.
Results
Since the launch of the DSS in mid-2002, to the end of
September 2008, 655 deaths were observed in a total of 77179
person-years among individuals aged 15–59 years old, a crude
death rate of 8.5 per 1000 person-years. Cause of death was un-
specifiable for 6% (40/655) of deaths.
Initially all analysis of mortality trends was done separately for
the two 12-month time periods in which there was an ART clinic
in the DSS area. Mortality rates were very similar in these two
time periods, so only the combined results are shown.
Among individuals aged 60+ years old, the all-cause mortality
rate was little changed over the 6-year period, with mortality rates
per 1000 person-years of 43.6 (149 deaths in 3414 person-years)
pre-ART, 41.5 (95 deaths in 2290 person-years) during ART
period 1, and 39.4 (147 deaths in 3731 person-years) during ART
period 2. Corresponding rate ratios (RR), compared with the pre-
ART period and adjusted for area of residence and sex, were 0.99
(95% CI 0.77–1.29) and 0.95 (95% CI 0.75–1.19) respectively.
All-cause mortality in 15–59 year olds
Compared with the pre-ART period, the all-cause mortality
rate fell by 16% during the time period when ART was available
only in the town 70 km from the DSS area (July 2005 to
September 2006), and by around one-third in ART period 2
following the opening of a clinic providing ART within the DSS
area (p,0.001, Table 1). The all-cause mortality rates were 10.2,
8.5, and 6.9 per 1000 person-years respectively during these three
time periods (Table 1). Using the pre-ART and ART period 2
mortality rates to construct two survival curves, the impact of the
mortality reduction is seen from around age 25. The probability of
surviving to age 60 is 57% in ART period 2 compared with 46%
in the pre-ART period (Figure 1).
The mortality reduction was larger in the ‘‘rural roadside’’ area
(from 13.2 in the pre-ART period to 7.8 per 1000 person-years in
ART period 2, a fall of 41%) than in the ‘‘rural remote’’ area
(where the mortality rate fell from 6.9 to 6.0 per 1000 person-
years, a 13% reduction), with statistical evidence that the time
trend was different in the two areas (p = 0.04). Reductions in
mortality were similar in men and women, though there was weak
evidence that the reduction happened earlier among women
(p = 0.12). The overall patterns were seen in each of the three age
groups, but less strongly in the oldest age group.
AIDS mortality in 15–59 year olds
AIDS mortality fell dramatically following ART roll-out, by
24% after the first clinic was opened, and by 57% after ART was
available within the DSS area, compared with the pre-ART time
period (Table 2). The AIDS mortality rates were 6.4, 4.6, and 2.7
per 1000 person-years respectively during these three time periods
(Table 2). The large mortality reduction in ART period 2 was seen
in both areas, for men and women, and in all age groups.
Although the reductions in AIDS mortality were larger in the
‘‘rural roadside’’ area than the ‘‘rural remote’’ area, there was no
statistical evidence that the trends were different in the two areas
(p = 0.28).There was weak evidence that the reduction in AIDS
mortality was larger for women than men (p = 0.07).
Non-AIDS mortality in 15–59 year olds
Overall, non-AIDS mortality was slightly higher in the time
period following ART roll-out compared with the pre-ART time
period (Table 3): the non-AIDS mortality rates were 3.8, 3.9, and
4.2 per 1000 person-years in the pre-ART period, ART period 1
and ART period 2 respectively (Table 3). In the ‘‘rural roadside’’
area, where reductions in AIDS mortality were very large, there
was little change in non-AIDS mortality. In the ‘‘rural remote’’
area there was an increase in non-AIDS mortality in both of ART
period 1 and period 2 compared with the pre-ART period, but
there was no evidence of an increasing trend in non-AIDS
mortality within the time period following ART roll-out. Among
men, non-AIDS mortality changed little over time. Among
women, in whom the reduction in AIDS mortality was especially
dramatic, there was weak evidence of an increase in mortality that
was not attributed to AIDS. There was little change over time for
each of the 3 age groups.
ART uptake
Among 14951 individuals aged 15–59 years old who were
resident in the DSS area at the time of the 2007/2008 sero-survey,
20.3% (3032/14951) were not found at home or refused to be
interviewed, 12.4% (1860/14951) were found and agreed to
answer questions (including on previous HIV testing history and
prior or current use of ART) but not to give blood for HIV testing,
and 67.3% (10059/14951) agreed to answer questions and also
gave blood for HIV testing (Figure S1).
Among the 10059 who gave blood for testing, an HIV test
result was available for 99.9% (10048/10059), 97.2% were given
their HIV test result (9762/10048), and 8.0% (805/10048) had
an HIV-positive test result. Twenty-four percent (190/805)
reported that they had taken ART, and the Weibull regression
model predicted that 31% were in need of ART in 2008
(Table 4), so that uptake as a proportion of those in need was
around 77%. The Weibull model was a good fit to the data,
ART and Mortality in Malawi
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illustrated by the fact that the observed median age at death
(34.0 years) was close to that predicted by the model (32.0 years).
Uptake was higher among women than men and higher among
individuals resident in the ‘‘rural roadside’’ than ‘‘rural remote’’
area. Among the 1860 individuals who answered questions but
did not give blood for testing on this occasion, 78 were already
known to be HIV-positive (from tests conducted during other
research studies), and of these 18% (14/78) reported that they
had taken ART.
Further calculations were done to estimate the total number of
individuals on ART in the surveillance area, allowing for non-
response. Among all individuals who gave blood for testing, 1.9%
(190/10059) reported that they had taken ART, and among all
individuals who answered questions but did not give blood for
testing, 2.0% (38/1860) reported that they had taken ART. If we
assume that ART uptake is 2% among the 20% of individuals who
were not found at home or refused to be interviewed, then a
further 61 individuals aged 15–59 years old would have been
Table 1. All-cause mortality in individuals aged 15–59 years old, by 3 time periods pre-ART and following ART roll-out, overall and
stratified by area of residence, sex, and age group.
Deaths/PYO1 Rate/1000 PYO Rate ratio (crude)
Rate ratio (adjusted)2,
95% CI and p-value
Entire study population
Pre-ART 288/282853 10.2
ART period 1 158/18514 8.5 0.84 0.84 (0.70–1.03), p = 0.09
ART period 2 209/30380 6.9 0.68 0.68 (0.57–0.82), p,0.001
By area of residence
‘‘Rural remote’’
Pre-ART 93/13476 6.9
ART period 1 73/9596 7.6 1.10 1.13 (0.83–1.53), p = 0.45
ART period 2 95/15842 6.0 0.87 0.87 (0.65–1.16), p = 0.34
‘‘Rural roadside’’
Pre-ART 195/14808 13.2
ART period 1 85/8918 9.5 0.72 0.72 (0.56–0.93), p = 0.01
ART period 2 114/14538 7.8 0.60 0.59 (0.47–0.74), p,0.001
By sex
Men
Pre-ART 130/13473 9.6
ART period 1 84/8811 9.5 0.99 1.00 (0.76–1.32), p = 0.99
ART period 2 102/14407 7.1 0.73 0.73 (0.56–0.95), p = 0.02
Women
Pre-ART 158/14812 10.7
ART period 1 74/9703 7.6 0.71 0.74 (0.56–0.97), p = 0.03
ART period 2 107/15972 6.7 0.63 0.64 (0.50–0.82), p,0.001
By age group
15–29 years old
Pre-ART 59/16395 3.6
ART period 1 31/10601 2.9 0.81 0.84 (0.54–1.30), p = 0.44
ART period 2 40/17060 2.3 0.65 0.67 (0.45–1.01), p = 0.06
30–44 years old
Pre-ART 147/7870 18.7
ART period 1 79/5384 14.7 0.79 0.81 (0.62–1.07), p = 0.13
ART period 2 102/9139 11.2 0.60 0.62 (0.48–0.80), p,0.001
45–59 years old
Pre-ART 82/4020 20.4
ART period 1 48/2530 19.0 0.93 0.95 (0.67–1.36), p = 0.79
ART period 2 67/4180 16.0 0.79 0.81 (0.58–1.11), p = 0.19
1PYO – person-years of observation;
2Entire study population, adjusted for area of residence, sex and age group; Stratified by area of residence, adjusted for sex and age group; Stratified by sex, adjusted for
area of residence and age group; Stratified by age, adjusted for area of residence and sex;
3these figures differ slightly from those published in 2008, due to minor corrections to the data since then.
doi:10.1371/journal.pone.0013499.t001
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taking ART at the time of the sero-survey, to give an estimated
total of 289 individuals taking ART.
Following HIV testing in the sero-survey, all HIV-positive
individuals who learnt their status were referred to HIV care
services, and 52 initiated ART between end January 2008, when
the ART cohort study was initiated, and end September 2008.
Among individuals who consented to be interviewed but did not
give blood for testing, and among individuals who did not
participate in the sero-survey, respectively 4 and 10 individuals
started ART during this time. We thus estimate that around 355
(289+52+4+10= 355) individuals were taking ART by the end of
September 2008 (Figure S1). This is an approximate figure: it
includes new ART patients without subtracting any who died after
they were seen in the sero-survey, but misses those who were on
ART but did not report this.
In a sero-survey conducted in 2005/2006 among around 10%
of the adult population in the DSS area, 38% of HIV-positive
individuals were in need of ART, based on clinical staging and
CD4 count data[27]. If we assume an overall HIV prevalence of
10% among the 14951 individuals aged 15–59 years old in the
DSS population (allowing for higher HIV prevalence in those
not tested in 2007/8, and compatible with the 11.4% found in
the 2005/6 survey), and that 34% of HIV-positive individuals
are in need of ART (midway between the two estimates of 31%
and 38%), then a total of 508 individuals would be in need of
ART.
Survival after starting ART, and mortality prior to starting
ART among individuals registered for care at the ART
clinic within the DSS area
Among 194 individuals who registered at the ART clinic within
the DSS area between January 2008 and June 2009, and started
ART, retention in care at 3 months was 94% and at 12 months
91%. Among 112 individuals who were either not eligible, or too
sick, to start ART at the time of first screening, 3.6% died and
2.7% were lost to follow-up.
Discussion
Our findings show that three years after the start of ART clinics
in rural, northern Malawi there has been a substantial reduction in
all-cause and AIDS mortality among people aged 15–59 years old.
For all-cause mortality, our best estimate is that mortality has
fallen by one-third during the second and third years of ART roll-
out in the district, compared with the pre-ART period, and for
AIDS mortality our best estimate is that it has fallen by around
57%. These dramatic reductions have occurred with the adoption
of a ‘‘public health’’ approach to ART delivery, which has enabled
a rapid increase in treatment coverage and accessibility of care
while still achieving good treatment outcomes[10].
It is striking that the overall mortality reduction is much larger
since an ART clinic opened within the study area, making
treatment more accessible than it was during the first year of ART
roll-out. From the start of the third year of ART roll-out in the
district, uptake of ART was also enabled by the sero-survey: 65%
of adults aged 15–59 years old learnt their HIV status, several
hundred were referred to HIV care services, and 52 initiated ART
between the end of January and the end of September 2008. The
cohort study provision of consistently available CD4 counts at the
local clinic may also have enhanced treatment access compared
with other areas of Malawi. Even with the opening of the ART
clinic in the DSS area, the reduction in all-cause and AIDS
mortality remained greater in areas that were closer to the tarmac
road, providing additional evidence of the importance of making
services as accessible as possible. The relatively low HIV
prevalence in the more remote areas also contributes to the lower
reduction in all-cause mortality in these areas.
Our estimates of the reduction in all-cause mortality are
compatible with estimates of ART need, known levels of ART
Figure 1. Probability of survival by age in years, separately for the pre-ART period and ART period 2.
doi:10.1371/journal.pone.0013499.g001
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uptake, and known levels of survival on ART among individuals
registered at the clinic that provides ART, in the study area. We
have estimated that around 355 individuals were taking ART, with
around 508 individuals in need of ART, during the time period
covered by the 2007/8 sero-survey. Given that 63% of deaths
were attributed to AIDS during the period 2002-5, then if we
assume treatment coverage of 70% (355/508), and that the
‘‘efficacy’’ of ART during the first 2–3 years of ART roll-out is to
avert 75% of AIDS deaths among individuals on ART (which is
broadly compatible with published data on retention in care in
Malawi and with data from the clinic in the DSS area), then the
proportion of deaths in the population averted by ART provision
(the population attributable fraction) would be 33% (i.e.
0.6360.7060.75), very similar to the observed reduction.
Other evidence that observed reductions in mortality are due to
ART is that there was little change in either non-AIDS mortality
or in mortality among individuals aged 60+ years old during the
period following ART roll-out. The slight increase in non-AIDS
mortality during the period following ART roll-out may be due to
misattribution of cause of death. Verbal autopsy reviewers were
more likely to have access to information on HIV status in the time
period following ART roll-out; as a consequence, the number of
Table 2. AIDS mortality in individuals aged 15–59 years old, by 3 time periods pre-ART and following ART roll-out, overall and
stratified by area of residence, sex, and age group.
Deaths/PYO1 Rate/1000 PYO Rate ratio (crude)
Rate ratio (adjusted)2,
95% CI and p-value
Entire study population
Pre-ART 180/28285 6.4
ART period 1 86/18514 4.6 0.73 0.76 (0.58–0.98), p = 0.03
ART period 2 81/30380 2.7 0.42 0.43 (0.33–0.56), p,0.001
By area of residence
‘‘Rural remote’’
Pre-ART 57/13476 4.2
ART period 1 34/9596 3.5 0.84 0.87 (0.57–1.33), p = 0.52
ART period 2 37/15842 2.3 0.55 0.56 (0.37–0.85), p = 0.006
‘‘Rural roadside’’
Pre-ART 123/14808 8.3
ART period 1 52/8918 5.8 0.70 0.70 (0.51–0.97), p = 0.03
ART period 2 44/14538 3.0 0.36 0.36 (0.26–0.51), p,0.001
By sex
Men
Pre-ART 67/13473 5.0
ART period 1 42/8811 4.8 0.96 0.98 (0.67–1.45), p = 0.94
ART period 2 41/14407 2.8 0.57 0.58 (0.39–0.85), p = 0.006
Women
Pre-ART 113/14812 7.6
ART period 1 44/9703 4.5 0.59 0.62 (0.44–0.88), p = 0.007
ART period 2 40/15972 2.5 0.33 0.34 (0.24–0.49), p,0.001
By age group
15–29 years old
Pre-ART 33/16395 2.0
ART period 1 14/10601 1.3 0.66 0.69 (0.37–1.29), p = 0.24
ART period 2 8/17060 0.5 0.23 0.25 (0.11–0.53), p,0.001
30–44 years old
Pre-ART 102/7870 13.0
ART period 1 48/5384 8.9 0.69 0.72 (0.51–1.02), p = 0.06
ART period 2 48/9139 5.3 0.41 0.43 (0.30–0.60), p,0.001
45–59 years old
Pre-ART 45/4020 11.2
ART period 1 24/2530 9.5 0.85 0.88 (0.54–1.45), p = 0.63
ART period 2 25/4180 6.0 0.53 0.56 (0.34–0.91), p = 0.02
1PYO – person-years of observation;
2Entire study population, adjusted for area of residence, sex and age group; Stratified by area of residence, adjusted for sex and age group; Stratified by sex, adjusted for
area of residence and age group; Stratified by age, adjusted for area of residence and sex.
doi:10.1371/journal.pone.0013499.t002
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HIV-negative individuals whose cause of death was wrongly
assigned to AIDS (because they had an AIDS-like clinical
condition) will have fallen. Nonetheless, our estimates of 6.4 per
1000 person-years for the pre-ART AIDS mortality rate
(corresponding to 6.4 per 100 person-years among HIV-positive
individuals if we assume HIV prevalence of 10%), and 3.8 per
1000 person-years for the non-AIDS mortality rate, are broadly in
line with published data from Southern and East Africa on the
mortality of HIV-positive and HIV-negative individuals[32,34].
This provides confidence that, at the population-level, verbal
autopsies are a useful tool for estimating the proportion of deaths
that are due to AIDS.
Our findings are also in line with other studies of the
population-level impact of ART on AIDS mortality in the early
years of ART roll-out. The estimated 57% (95% CI 44–67%)
reduction in AIDS mortality with ART coverage of around 70%
found in our study is consistent with a 50% reduction in Addis
Ababa during 2 years in which ART uptake was apparently very
high[21] as well as the approximately 25% reduction in a rural
area of South Africa with ART uptake averaging around 40% of
those in need during the first 3 years of ART roll-out[22], and a
37% fall in registered deaths in a district of southern Malawi with
treatment coverage estimated to be around 80%[24]. Overall, our
findings support the roll-out of ART treatment to health centres
Table 3. Non-AIDS mortality in individuals aged 15–59 years old, by 3 time periods pre-ART and following ART roll-out, overall and
stratified by area of residence, sex, and age group.
Deaths/PYO1 Rate/1000 PYO Rate ratio (crude) Rate ratio (adjusted)2, 95% CI and p-value
Entire study population
Pre-ART 108/28285 3.8
ART period 1 72/18514 3.9 1.02 1.03 (0.76–1.39), p = 0.86
ART period 2 128/30380 4.2 1.10 1.10 (0.85–1.42), p = 0.47
By area of residence
‘‘Rural remote’’
Pre-ART 36/13476 2.7
ART period 1 39/9596 4.1 1.52 1.53 (0.97–2.42), p = 0.07
ART period 2 58/15842 3.7 1.37 1.36 (0.89–2.07), p = 0.15
‘‘Rural roadside’’
Pre-ART 72/14808 4.9
ART period 1 33/8918 3.7 0.76 0.75 (0.50–1.14), p = 0.18
ART period 2 70/14538 4.8 0.99 0.97 (0.70–1.35), p = 0.86
By sex
Men
Pre-ART 63/13473 4.7
ART period 1 42/8811 4.8 1.02 1.02 (0.69–1.51), p = 0.93
ART period 2 61/14407 4.2 0.91 0.89 (0.63–1.27), p = 0.53
Women
Pre-ART 45/14812 3.0
ART period 1 30/9703 3.1 1.02 1.04 (0.65–1.65), p = 0.88
ART period 2 67/15972 4.2 1.38 1.39 (0.95–2.03), p = 0.09
By age group
15–29 years old
Pre-ART 26/16395 1.6
ART period 1 17/10601 1.6 1.01 1.03 (0.56–1.90), p = 0.92
ART period 2 32/17060 1.9 1.18 1.20 (0.72–2.02), p = 0.48
30–44 years old
Pre-ART 45/7870 5.7
ART period 1 31/5384 5.8 1.01 1.02 (0.64–1.61), p = 0.93
ART period 2 54/9139 5.9 1.03 1.05 (0.70–1.56), p = 0.82
45–59 years old
Pre-ART 37/4020 9.2
ART period 1 24/2530 9.5 1.03 1.03 (0.62–1.73), p = 0.90
ART period 2 42/4180 10.0 1.09 1.09 (0.70–1.70), p = 0.69
1PYO – person-years of observation;
2Entire study population, adjusted for area of residence, sex and age group; Stratified by area of residence, adjusted for sex and age group; Stratified by sex, adjusted for
area of residence and age group; Stratified by age, adjusted for area of residence and sex
doi:10.1371/journal.pone.0013499.t003
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and clinics with unsophisticated facilities: we believe that increased
access to ART is the primary reason for the sustained fall in all-
cause and AIDS mortality, although the sero-survey conducted in
2007/8 made a contribution and other temporal changes in
health-seeking behaviour might also have made a difference.
A key question is whether the reduction in all-cause and AIDS
mortality can be sustained or even increased. ART coverage in the
study area is already around 70% using current treatment criteria
in Malawi, but recently adjusted criteria will see the numbers of
HIV-infected adults who are eligible for ART increase[35], while
increased access to HIV testing and increased confidence in the
health care system will enlarge the numbers seeking care. Set
against this, enhancing access may be constrained because many
clinics in Malawi are already operating at high capacity[10], and
further task-shifting will probably be required[36]. Roll-out of
ART to the next layer of health clinics and health posts seems
justified in order to further increase access and limit the impact of
the ART programme on hospital facilities, whilst increasing the
capacity to manage the rising number of HIV-infected individuals
who need treatment. Localising care is also expected to enhance
adherence to therapy and retention in treatment programmes.
It has been recognised that the early years of ART roll-out are a
‘‘honeymoon’’ period during which it is possible to avert a high
proportion of AIDS deaths[10]. Dramatic mortality reductions at
the population level can be sustained only if the survival of
individuals on ART is prolonged for as long as possible, rather
than for only a few years, and if HIV prevention measures are
implemented at the same time since HIV prevalence will increase
due to ART provision unless HIV incidence simultaneously falls.
In conclusion, our study shows that ART can have a dramatic
effect on mortality in a resource-constrained setting in Africa, at
least in the early years of treatment provision. Continued
monitoring of this effect is essential, to confirm if it can be
sustained and to anticipate and plan changes to continue this
successful intervention. Continued funding to maintain and
further scale-up treatment provision will bring large benefits in
terms of saving lives.
Supporting Information
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